• Publications
  • Influence
mRNA Expression of Growth Factors in Glomeruli From Diabetic Rats
TLDR
The data indicate that alterations in growth factor mRNA levels in glomeruli may be a manifestation of diabetic nephropathy, and that hyperglycemia or insulin deficiency may play a role in abnormal growth factor gene regulation.
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
TLDR
Nicotinamide may provide an alternative for controlling hyperphosphatemia and hyperparathyroidism without inducing hypercalcemia in hemodialysis patients.
The Urinary Podocyte as a Marker for the Differential Diagnosis of Idiopathic Focal Glomerulosclerosis and Minimal-Change Nephrotic Syndrome
TLDR
Urinary podocytes may be a useful diagnostic indicator for differentiation between FGS and minimal-change nephrotic syndrome and may also mark disease progression in cases of FGS.
Effect of Cerivastatin on Urinary Albumin Excretion and Plasma Endothelin-1 Concentrations in Type 2 Diabetes Patients with Microalbuminuria and Dyslipidemia
TLDR
The use of cerivastatin is associated with decreased microalbuminuria and plasma and urinary ET-1 levels in micro Albuminuric patients with type 2 diabetic mellitus and it is speculated that this may represent an amelioration of renal injury.
Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
TLDR
Urinary l-FABP levels appear to be associated with the progression of diabetic nephropathy, and pitavastatin may be effective in ameliorating tubulointerstitial damage in early diabetic neephropathy.
Effects of Angiotensin-Converting Enzyme Inhibitor, Angiotensin II Receptor Antagonist and Calcium Antagonist on Urinary Podocytes in Patients with IgA Nephropathy
TLDR
The data suggest that urinary podocytes may be a marker of disease activity in adult patients with IgA nephropathy and that trandolapril and candesartan cilexetil are more effective than verapamil in reducing the number of podocytes.
Azelnidipine Reduces Urinary Protein Excretion and Urinary Liver-Type Fatty Acid Binding Protein in Patients with Hypertensive Chronic Kidney Disease
TLDR
Azelnidipine is renoprotective in hypertensive patients with mild CKD and this action is, at least in part, due to the anti-oxidative effect.
Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy.
TLDR
Urinary L-FABP level can serve clinically as a predictive marker for contrast medium-induced nephropathy, and occurred in 13 of 66 patients.
...
...